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ABBREVIATIONS LIST 
6MW: 6-minute walk  
CI: cardiac index 
CO: cardiac output 
CPET: cardiopulmonary exercise testing 
CW: clinical worsening 
LV: left ventricular 
LV A wave PW: pulsed waved left ventricular A wave  
LV E wave PW: pulsed waved left ventricular E wave  
LV-EId: left ventricular diastolic eccentricity index 
LV-EIs: left ventricular systolic eccentricity index 
mPAP: mean pulmonary artery pressure 
PAH: pulmonary arterial hypertension  
IPAH: idiopathic PAH  
PAWP: pulmonary artery wedge pressure 
PETCO2 peak: end-tidal carbon dioxide partial pressure 
PH: pulmonary hypertension 
PVR: pulmonary vascular resistance 
RA: right atrium 
RV: right ventricular 
RVEDA: RV end-diastolic area 
RVESA: RV end-systolic area 
RVFAC: RV fractional area change  
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SV: stroke volume 
TAPSE: tricuspid annular plane systolic excursion 
VCO2 peak: peak carbon dioxide output 
VE: minute ventilation 
VO2 peak: peak oxygen uptake 
WHO: World Health Organization 
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ABSTRACT  
Background. Right ventricular (RV) function is a major determinant of exercise intolerance 
and outcome in idiopathic pulmonary arterial hypertension (IPAH). The aim of the study 
was to evaluate the incremental prognostic value of echocardiography of the RV and 
cardiopulmonary exercise testing (CPET) on long-term prognosis in these patients. 
Methods. One hundred-thirty treatment-naïve IPAH patients were enrolled and 
prospectively followed. Clinical worsening (CW) was defined by a reduction in 6-minute 
walk distance plus an increase in functional class, or non elective hospitalization for PAH, 
or death. Baseline evaluation included clinical, hemodynamic, echocardiographic and 
CPET variables. Cox regression modeling with c-statistic and bootstrapping validation 
methods were done. 
Results. During a mean period of 528 ± 304 days, 54 patients experienced CW (53%). 
Among demographic, clinical and hemodynamic variables at catheterization, functional 
class and cardiac index were independent predictors of CW (Model-1). With addition of 
echocardiographic and CPET variables (Model-2), peak O2 pulse (peak VO2/heart rate) 
and RV fractional area change (RVFAC) independently improved the power of the 
prognostic model (AUC: 0.81 vs 0.66, respectively; p=0.005). Patients with low RVFAC 
and low O2 pulse (low RVFAC + low O2 pulse) and high RVFAC+low O2 pulse showed 
99.8 and 29.4 increase in the hazard ratio, respectively (relative risk -RR- of 41.1 and 25.3, 
respectively), compared with high RVFAC+high O2 pulse (p=0.0001).  
Conclusions. Echocardiography combined with CPET provides relevant clinical and 
prognostic information. A combination of low RVFAC and low O2 pulse identifies patients 
at a particularly high risk of clinical deterioration.   
 
Keywords: pulmonary arterial hypertension, right ventricular systolic function, 
echocardiography, cardiopulmonary exercise test, clinical worsening.
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INTRODUCTION 
Pulmonary arterial hypertension (PAH) is a life-threatening and still incurable syndrome 
caused by an unexplained progressive increase in pulmonary vascular resistance (PVR).1 
PAH exercise symptomatology and outcome are mainly determined by right ventricular 
(RV) function adaptation to increased afterload.2  
The diagnosis of PAH requires a right heart catheterization with measurement of the mean 
pulmonary arterial pressure (mPAP) ≥ 25 mmHg and a PVR of > 3 Wood units.3 However, 
the procedure allows only an indirect decription of RV function, with right atrial pressure 
(RAP) to estimate RV end-diastolic volume (EDV), or preload, mPAP or PVR to estimate 
afterload, and stroke volume (SV) to reflect contractility. 4  Echocardiography provides 
indices of systolic and diastolic function, structural changes, RV-left ventricular (LV) 
interactions in addition to estimations of afterload.5 On the other hand, cardiopulmonary 
exercise testing (CPET) allows for indirect assessment of RV functional contractile reserve 
determining maximum cardiac output and related maximum workload and oxygen uptake 
(VO2 max).6,7,8  
Recent studies have shown the incremental value and prognostic relevance of 
echocardiography of the RV combined to CPET variables in predicting outcome in patients 
with heart failure.9  This has not been yet assessed in PAH. Furthermore, the added value 
of echocardiography and CPET with respect to invasive hemodynamic predictors of 
outcome is not exactly known. Therefore, the aim of the present study was to evaluate the 
incremental prognostic value of echocardiography and CPET on long-term prognosis 
compared with traditional clinical and hemodynamic variables. 
 
METHODS 
Population and study design 
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This study enrolled 130 consecutive idiopathic PAH (IPAH) patients referred for pulmonary 
hypertension (PH) to our center over a 3-year period and who gave an informed written 
consent. This study was conducted in accordance with the amended Declaration of 
Helsinki and was approved by the local Institutional Review Board (Protocol n. 42412). 
The diagnosis of IPAH relied on right heart catheterization showing precapillary pulmonary 
hypertension (mPAP ≥ 25 mmHg, pulmonary artery wedge pressure-PAWP ≤ 15 mmHg) 
and the use of an algorithm incorporating respiratory function tests, perfusion lung scan, 
computer tomography scan and echocardiography to exclude secondary causes, in 
agreement with updated guidelines.1 Patients were then treated with endothelin receptor 
antagonists - ERA, phosphodiesterase 5 inhibitors - PDE5i, and prostanoids.1  
Clinical worsening (CW) was defined as a reduction from baseline in the 6-minute walk 
(6MW) distance by 15%, confirmed by 2 tests done within 2 weeks, plus worsening of 
World Health Organization (WHO) functional class, or nonelective hospitalization for PAH 
(need for i.v. diuretic or inotropic drugs, need for new PAH therapies, lung transplantation, 
or septostomy), or all-cause mortality.10  
All patients were prospectively followed-up with phone calls (every month) and clinical 
examinations (every 1-3 months) by two physicians (R.P and B.P.) blinded to the 
echocardiography and CPET results.  The first episode of CW was taken into 
consideration for the analysis.  
 
Echocardiographic assessment  
Baseline echocardiographic studies were performed within 24 hours of the RHC using 
commercially available equipment (Vivid S6, GE), with a 3.5-MHz transducer at a depth of 
16 cm in the standard views and in agreement with the American Society of 
Echocardiography Guidelines.5 
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The following standard parameters and derived measures were considered in the analysis: 
- apical 4 chamber view: right atrial area (RA area), RV end-diastolic area (RVEDA), RV 
end-systolic area (RVESA), RV fractional area change % [RVFAC=(RVEDA - 
RVESA)/RVEDA x 100] and tricuspid annular plane systolic excursion (TAPSE); 
- parasternal view: left ventricular systolic and diastolic eccentricity index (LV-EIs and LV-
EId, respectively) and presence of pericardial effusion.  
Intraobserver and interobserver variabilities were assessed using a Bland-Altman analysis  
for RVEDA and RVESA, the two determinants of RVFAC: for RVEDA, the intraobserver 
variability was 0.18 ± 0.66 cm2 (95% confidence interval [CI]: -1.09 to 1.45) and 
interobserver variability was 0.31 ± 0.98 cm2 (95% CI: -1.37 to 1.99); for RVESA the 
intraobserver variability was 0.16 ± 0.50 cm2 (95% CI: -0.77 to 1.09) and the interobserver 
variability was 0.05 ± 0.55 cm2 (95% CI: -1.10 to 1.20). 
 
Six-minute walk test 
At baseline all patients performed a non-encouraged 6MW test in a 25-m-long corridor in 
the same environmental conditions and at about the same time of day (±2 h).  
The best distance covered on two consecutive tests performed after 60-90 min was 
considered for the analysis.11  
 
Cardiopulmonary exercise test  
All patients performed a symptom-limited incremental cycle ergometer CPET with 10-15 
Watt/min workload increments. No patient performed the test on supplemental O2. 
Oxygen uptake (VO2), carbon dioxide output (VCO2), minute ventilation (VE) and end-tidal 
carbon dioxide partial pressure (PETCO2) were measured breath-by-breath (Quark CPET, 
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Rome, Italy) and averaged every 5 s for subsequent analysis. Heart rate (HR) was 
monitored via 12 leads ECG.  The O2 pulse was calculated as the VO2/HR ratio at peak 
exercise. Tests were considered maximal if peak respiratory exchange ratio (RER) was 
greater than 1.1. The anaerobic threshold was detected by the V-slope method.12   
Peak work rate (WR), peak VO2 and peak VE were defined, respectively, as the highest 
level of exercise and the highest VO2 and VE that could be sustained for at least 15 s 
during the last stage of incremental exercise. The slope of VE over VCO2 (∆VE/∆VCO2) 
during incremental test was measured from unloaded pedalling to the ventilatory 
compensation point (VCP) and, for patients who did not reached the VCP it was measured 
from unloaded pedalling to peak exercise. The dead space volume of the facemask was 
subtracted from the total VE before calculating individual VE/VCO2 slopes and ratios.  
The occurrence of a right-to-left exercise-induced shunt through a patent foramen ovale 
was detected by brisk increase in VE/VCO2 and other criteria as previously described.13  
 
Statistical analysis  
Continuous data were expressed as mean ± SD, and categorical data were expressed as 
counts and proportions. Two-group comparisons were done with unpaired or paired, two-
tailed t tests for means if the data were normally distributed or with Wilcoxon’s rank-sum 
tests if the data were not normally distributed. Chi square or Fisher’s exact tests were 
used to analyze the categorical data. Linear regression analysis was performed to assess 
the relationship between RVFAC and PVR and expressed as a Pearson correlation 
coefficient. 
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Actuarial freedom from episodes of CW was determined by the Life Table method. Kaplan- 
Meier (product-limit) graphs were used to demonstrate clinical worsening over time. 
Patients who were without CW were censored on the date of the conclusion of the study. 
Cox proportional hazards regression methods were used to identify risk factors for CW and 
to determine the association among baseline patient characteristics and outcomes. Time 
to clinical worsening was selected as the primary outcome. Univariate proportional 
hazards analyses were performed, and Wald chi-square p values were calculated. The 
likelihood ratio method was used to determine hazard ratios. After all Cox univariate 
analyses were performed, the covariates were inversely ordered by p value (smallest to 
largest).  
Because of the large number of variables and relatively low number of events (54), a strict 
univariate p-value criterion (p, 0.05) was used to select the variables initially entered into 
the multivariable model. Thus, these variables were included in the multivariable model if 
they improved the likelihood ratio statistic by an amount that corresponded to a p value of 
<0.05.  
Finally, collinearity was assessed by using bivariate linear regression between continuous 
variables or using Wilcoxon tests across categorical variables. When 2 or more selected 
variables were intimately associated (correlation coefficient >0.60, as between CI, 6MW 
test, PAP, PVR, peak VO2, VE/VCO2 slope, and between RVEDA, RVESA, RVFAC, 
TAPSE, LV-EI, and between RAP, RA area, pericardial effusion), the one chosen was that 
with the greatest Wald statistic, ie the ratio of the square of the regression coefficient to the 
square of the standard error of the coefficient. The Wald statistic, analogous to the t-test in 
linear regression, is used to assess the significance of coefficients thus the contribution of 
individual predictors in a given model and is asymptotically distributed as a chi-square 
distribution. 
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This approach allowed to restrict the candidate variables for the multivariate analysis to the 
CI, RAP, WHO class, 6MW test for Model-1 building and to the CI, WHO class, PETCO2, 
peak pulse O2, RVFAC, pericardial effusion for Model-2 construction.  
Finally, internal validation of the Cox proportional hazard analysis model was based on 
bootstrapping, using 10.000 bootstrap samples and 95% percentile confidence intervals.14 
The c statistic was calculated for each model and the comparison of the two values was 
tested by the method of DeLong et al. 15  to determine the incremental prognostic 
information of Model-2.  
Receiver operating characteristic (ROC) curves were used to identify the optimal RVFAC 
and peak O2 pulse cut-points for CW detection. Survival curves were generated using the 
Kaplan-Meier method, and the log-rank test was used to evaluate differences between 
groups. 
All statistical analyses were performed using SPSS software (version 20.0, IBM) and Stata 
13 (StataCorp, College Station, TX, USA). All statistical tests were 2-sided, and a p value 
<0.05 was considered statistically significant. 
 
RESULTS  
Among 130 IPAH patients initially enrolled, 13 were excluded as being unable to perform 
the CPET, 8 because of an exercise gas exchange pattern indicating opening of a 
foramen ovale and 7 because of severe tricuspid regurgitation.  The remaining 102 were 
62 women and 40 men, aged 52 ± 14 yrs with a BMI of 25.5 ± 4, a WHO functional class 
of 2.7 ± 0.4, a 6MW distance 430 ± 6 m and severely impaired hemodynamics, 
echocardiography and exercise capacity (Table 1). Most relevant co-morbidities were 
diabetes (5 patients; 5%), hypercholesterolemia (10 patients; 10%), thyroid diseases (6 
patients; 6%), and clinical depression (7 patients; 7%). 
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Treatments instituted after diagnostic work-up were calcium channel blockers in 9, ERA in 
37, PDE5i in 6 and sc treprostinil in 16 patients.  
During a follow-up of 528 ± 304 days, 54 patients experienced CW (53%)(Table 2). The 
event-free survival rates were, respectively, 72%, 51% and 30% at 1, 2 and 3 years 
(Figure 1). As shown in Table 3, patients with a CW had worse WHO functional class, 
shorter 6MW test, worse hemodynamics, worse RV function on echocardiography and 
CPET with lower VO2 peak and increased VE/VCO2. 
At univariate analysis the following variables resulted predictive of CW (Table 4): WHO 
functional class, 6MW distance, RAP, CI, PVR, RA area, LV-EId, LV-EIs, RVEDA, 
RVESA, RVFAC, TAPSE, pericardial effusion, peak exercise HR, VO2 peak, VO2 pulse 
peak, VE peak, VE/VCO2 slope, peak workload. 
Cox regression Model-1 for CW prediction was constructed with those variables 
significantly resulting from univariate analysis excluding echocardiographic and CPET 
variables. Among demographic, clinical and hemodynamic parameters, WHO functional 
class and CI emerged as independent predictors of CW (Table 5). Adding 
echocardiographic and CPET variables from univariate analysis, Model-2 was generated, 
in which only peak O2 pulse and RVFAC emerged as additional independent predictors of 
outcome. Figures 2 and 3 highlight that among patients with preserved RVFAC at rest 
there was a proportion of them with low peak O2 pulse.  
The c-statistic accuracy comparison between the two models demonstrated incremental 
prognostic power of Model-2 versus Model-1 for CW (area under the curve: 0.81 vs 0.66, 
respectively; p=0.005, 95% C.I. 0.02 to 0.11) (Figure 4). Sensitivity analysis of the Cox 
proportional hazard analysis for a parsimonious Model-2 (including CI, WHO class, 
PETCO2, peak pulse O2, RVFAC and pericardial effusion) using boostrapping (Table 5) 
confirmed the main results, in terms of both statistical magnitude and direction. 
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ROC curve analysis revealed that RVFAC and peak O2 pulse at a cut-off point of 36.5% 
and 8.0 ml/beat, respectively, were indicators of CW with the best predictive values 
(RVFAC: AUC 0.89, p=0.0001; peak O2 pulse: AUC 0.91, p=0.0001). Figure 5 shows 
Kaplan-Meier event-free survival curves based on the combination of the cut-off values of 
RVFAC and peak O2 pulse. Patients with high RVFAC+high peak O2 pulse (Group 1) had 
a better prognosis compared with patients with high RVFAC+low peak O2 pulse (Group 2) 
and low RVFAC+low peak O2 pulse (Group 3).  
Bivariate Cox regression analysis applied to the combination of the binary values of 
RVFAC and peak O2 pulse showed a progressive increase in the hazard ratio from group 
2 to 3: HR 29.4 (C.I. 3.8-224; p=0.001) (RR 25.3) and HR 99.8 (C.I. 13.5-737; p=0.0001) 
(RR 41.1), respectively, compared with high RVFAC+high peak O2 pulse group (log-
likelihood -2, 323; χ2 80.6; p=0.0001). 
 
DISCUSSION 
The present results show that echocardiography and CPET are important additions to right 
heart catheterization to assess disease severity and predict outcome in patients with IPAH.  
The present study is original by the analysis of predictors of outcome of combined cardiac 
catheterization, echocardiography and CPET measurements. Only 2 variables emerged as 
additional independent predictors: RVFAC and peak O2 pulse. RVFAC is a surrogate of 
RV ejection franction (EF)5 and accordingly reflects systolic function at a given level of 
preload and afterload.2,16 MRI meaurements of changes,17 not absolute values of RVEF,18 
have been shown to be of prognostic relevance. The new finding here is that RVFAC 
outperformed other echocardiographic indices of systolic function. Each of these 
measurements has of course limitations5 and as previously shown4 whether or not a 
variable emerges as an independent predictor of outcome is also dependent on size and 
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characteristics of source population.  As for peak O2 pulse, this variable is thought to 
assess maximum SV.19 MRI-determined SV has been previously shown to be an important 
predictor of survival in PAH.17  
Right heart catheterization variables have long been known to predict survival in patients 
with PAH, with more effective prognostication from variables assessing RV function (SV, 
RAP) than from variables assessing pulmonary vascular function (PAP, PVR).20-27 
Accordingly, it is not surprising that several echocardiographic variables which estimate 
RV function have also been reported as independent predictors of outcome in PAH.27-41 
However, in all these studies there was no evaluation of the relevance and added value of 
each of them with respect to right heart catheterization  measurements.4 Only one study, 
by incremental modeling analysis using the c-index, has shown that the incorporation of 
invasive hemodynamic variables in a model that already include echocardiographic 
measures may not be of  incremental value to prognostic evaluation.41  
CPET is another important tool for the assessment of PAH severity and outcome, with 
variables emerging as independent predictors being the 6MW distance, peak VO2, 
VE/VCO2 and HR reserve.6,42-44 These CPET variables of predictive capability are the 
same as reported in heart failure,45 and are therefore assumed to be determined by RV 
function. However, as for echocardiography, the added value of CPET variables with 
respect to a right heart catheterization is not clearly determined. Only one study addressed 
this issue and showed PVR, peak VO2 and heart rate reserve as independent predictors of 
survival.6  
A limitation to this study is that IPAH patients with exercise-induced opening of a foramen 
ovale were excluded to preserve the relevance of ventilator measurements. These patients 
may have a worse prognosis.4 A re-analysis of our population with inclusion of patients 
with exercise-induced right-to-left shunting showed the same independent predictors of 
outcome with the same levels of significance. However, 15% (20 patients) of the initial 
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cohort were excluded which indeed is a limitation of the study. Another limitation is that 
there was no independent adjudication committee for clinical events. Finally, most 
parameters used in the evaluation of PH patients are to some extent physiologically linked, 
and this may not be sufficiently accounted for in a multivariate analysis. 
In conclusion, the present results strongly suggest that noninvasive measurements related 
to RV function obtained by combining resting echocardiography and CPET are of added 
value to right heart catheterization in the assessment of severity and prognostication of 
PAH.  
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Table 1. Hemodynamic, imaging and exercise characteristics of the study population. 
    
Normal values 
Hemodynamics   
mPAP, mmHg 48±15  
RAP, mmHg 7.5±4.1  
CI, l/min/m2 2.4±0.4  
PAWP, mmHg 9±3  
PVR, WU 9.7±5.1  
Echocardiography   
RA Area, cm2 31±10 10-18 
LV-EId 1.4±0.3 1.0 
LV-EIs 1.6±0.6 1.0 
RVEDA, cm2 27.5±7.3 10-25 
RVESA, cm2 17.2±5.9 4-14 
RVFAC, % 37.9±8.6 35-63 
TAPSE, mm 20±4 > 17 
Pericardial effusion 0.3±0.5 0 
Cardiopulmonary exercise test   
HR rest, beats/min 81±14  
HR peak, beats/min 128±24  
VO2 peak, ml/min 1050±359 1390-2780 
VO2/Kg peak, ml/min/Kg 15.3±4.1 20-36 
VO2 pulse peak, ml/beat 8.3±2.7 8-17 
VCO2 peak, ml/min 1050±399 1810-2450 
VE peak, l/min 52.8±20.3 46-110 
PETCO2 peak, mmHg 24.3±5.4 33-41 
VE/VCO2 slope  46±13 26-35 
Work peak, watts 66±30  
Follow-up, days 528±304  
     
 
 
CI: cardiac index; HR: heart rate; LV-EId: left ventricular end-diastolic eccentricity index; LV-EIs: left 
ventricular end-systolic eccentricity index; mPAP: mean pulmonary arterial pressure; PAWP: mean 
pulmonary artery wedge pressure; PETCO2 peak: end-tidal CO2 pressure; PVR: pulmonary vascular 
resistance; RA area: right atrium area; RAP: mean right atrial pressure; RVEDA: right ventricular end-
diastolic area; RVESA: right ventricular end-systolic area; RVFAC: right ventricular fractional area change; 
TAPSE: tricupid anular plane systolic excursion; VCO2 peak: peak carbon dioxide production; VE: minute 
ventilation; VE/VCO2 slope: ventilation to CO2 production slope; VO2 peak: peak oxygen uptake.  
Normal values for echocardiographic parameters are reported from reference 5. 
Normal values for cardiopulmonary exercise test have been calculated from previous reported equations and 
reports considering gender, age, height and weight.46,47  
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Table 2.  Description of different clinical worsening endpoints during follow-up.   
 
  N (%)  
6MW test + WHO class 24/54 (44.4%) 
Hospital admission RHF 16/54 (29.6%) 
Death: 14/54 (25.9/) 
RHF 9/14 (64.2%) 
Sudden death  1/14 (7.1%) 
Non cardiac death 4/14 (28.5%) 
    
 
6MW test: isolated worsening in six-minute walk test > 15% compared to previous test; WHO class: isolated 
worsening in World Health Organization functional class; 6MW test + WHO: worsening in both 6MW test and 
WHO class; Hospital admission RHF: hospital admission for right heart failure; RHF: right heart failure.  
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Table 3. Demographic, clinical, hemodynamic, imaging and exercise differences between 
patients with and without CW. 
  CW  no CW p 
Patients 54 48  
Age, years 52±16 52±12 ns 
BMI 24.8±4 25.9±4 ns 
WHO class 3.0±0.0 2.5±0.5 0.0001 
6MW test, m 397±53 461±59 0.0001 
Hemodynamics    
PAPm, mmHg 55±16 41±11 0.0001 
RAP, mmHg 9.1±4.7 5.9±2.6 0.0001 
CI, l/min/m2 2.3±0.4 2.7±0.3 0.0001 
PAWP, mmHg 8.9±3.5 9.5±3.0 ns 
PVR, WU 12.6±5.3 6.9±2.9 0.0001 
Echocardiography    
RA Area, cm2  34±10 27±9 0.0001 
LV-EId 1.5±0.3                                                                                                      1.2±0.2 0.0001 
LV-EIs 1.8±0.7 1.3±0.2 0.0001 
RVEDA, cm2 31±6 24±6 0.0001 
RVESA, cm2 21±5 14±4 0.0001 
RVFAC, % 32±7 43±6 0.0001 
TAPSE, mm 17.8±3.7 21.1±3.1 0.0001 
Cardiopulmonary exercise test    
HR rest, beats 84±14 79±14 ns 
HR peak, beats 124±26 132±21 ns 
VO2 peak, ml/min 806±165 1276±342 0.0001 
VO2/Kg peak, ml/min/Kg 12.7±2.5 17.8±3.8 0.0001 
VO2 pulse peak, ml/beat 6.5±0.9 10.1±2.6 0.0001 
VE peak, l/min 43.7±10.9 61.0±23,2 0.0001 
VCO2 peak, ml/min 804±214 1287±394 0.0001 
PETCO2 peak, mmHg 22.6±5.2 25.8±5.3 0.003 
VE/VCO2 slope  51±14 43±12 0.001 
Specific therapy    
Ca-channel blockers 4 (7.4%) 5 (10.4%) ns 
ERA 19 (35.1%) 18 (37.5%) ns 
PDE5i 18 (33.3%) 16 (33.3%) ns 
Epoprostenol i.v. 4 (7.4%) 2 (4.1%) ns 
Treprostinil s.c. 9 (16.6%) 7 (14.5%) ns 
        
 
 
6MW test: non-encouraged 6-minute walk test; BMI: body mass index; CI: cardiac index; CW: clinical 
worsening; ERA: endothelin receptor antagonist; HR: heart rate; LV-EId: left ventricular end-diastolic 
eccentricity index; LV-EIs: left ventricular end-systolic eccentricity index; mPAP: mean pulmonary arterial 
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pressure; PAWP: mean pulmonary artery wedge pressure PDE5i: phosphodiesterase 5 inhibitor; PETCO2 
peak: end-tidal CO2 pressure; PVR: pulmonary vascular resistance; RA area: right atrium area; RAP: mean 
right atrial pressure; RVEDA: right ventricular end-diastolic area; RVESA: right ventricular end-systolic area; 
RVFAC: right ventricular fractional area change; TAPSE: tricupid anular plane systolic excursion; VCO2 
peak: peak carbon dioxide production; VE: minute ventilation; VE/VCO2 slope: ventilation to CO2 production 
slope; VO2 peak: peak oxygen uptake; WHO: World Health Organization. 
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Table 4. Univariate analysis of baseline parameters for clinical worsening prediction. 
 
  
Unit Wald HR CI (95%) p  
WHO class 1 9.9 24.2 3.3-175 <0.0001 
6MW test, m 1 16.6 0.99 0.98-0.99 <0.0001 
Hemodynamics      
RAP, mmHg 1 13.3 1.10 1.04-1.16 <0.0001  
CI, l/min/m2 1 27.7 0.14 0.07-0.29 <0.0001   
PVR, WU 1 35.4 1.16 1.10-1.22 <0.0001  
Echocardiography      
RA Area, cm2 1 11.4 1.04  1.01-1.06 0.001 
LV-EId 1 20.7 5.37 2.60-11.06 <0.0001 
LV-EIs 1 32.9 3.42 2.25-5.22 <0.0001 
RVEDA, cm2 1 21.6 1.08 1.04-1.11 <0.0001 
RVESA, cm2 1 39.1 1.15 1.10-1.20 <0.0001 
RVFAC, % 1 51.1 0.86 0.83-0.90 <0.0001 
TAPSE, mm 1 18.0 0.85 0.79-0.92 <0.0001 
Pericardial effusion 1 7.3 2.16 1.23-3.77 0.007 
Cardiopulmonary 
exercise test 
     
HR peak, beats/min 1 4.7 0.98 0.97-0.99 0.02 
VO2/Kg peak, ml/min/Kg 1 28.1 0.77 0.70-0.85 <0.0001 
VO2 pulse peak, ml/beat 1 35.5 0.48 0.38-0.61 <0.0001 
VE peak, l/min 1 15.2 0.95 0.92-0.97 <0.0001 
VE/VCO2 slope  1 7.1 1.02 1.00-1.04 0.007 
Work peak, watts 1 11.7 0.97 0.96-0.98 0.001 
        
 
6MW test: non-encouraged 6-minute walk test; BMI: body mass index; CI: cardiac index; HR: heart rate; LV-
EId: left ventricular end-diastolic eccentricity index; LV-EIs: left ventricular end-systolic eccentricity index; 
mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; RA area: right atrium area; 
RAP: mean right atrial pressure; RVEDA: right ventricular end-diastolic area; RVESA: right ventricular end-
systolic area; RVFAC: right ventricular fractional area change; TAPSE: tricupid anular plane systolic 
excursion; VCO2 peak: peak carbon dioxide production; VE: minute ventilation; VE/VCO2 slope: ventilation to 
CO2 production slope; VO2 peak: peak oxygen uptake; Wald: ratio of the square of the regression coefficient 
to the square of the standard error of the coefficient; WHO: World Health Organization. 
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Table 5. Cox regression models for clinical worsening prediction (Model-1 and Model-2) 
and bootstrap estimates of Cox proportional hazard analysis. 
 
 Unit HR (95% CI) p C-statistic (95% CI) 
Model-1     0.66 (0.55-0.76) 
WHO class 1 15.8 (2.15-116) 0.007  
CI 0.5 0.49 (0.33-0.70) 0.0001  
Model-2     0.81 (0.72-0.88) 
RVFAC 1 0.91 (0.86-95.0) 0.0001  
O2 pulse 1 0.62 (0.48-0.79) 0.0001  
Bootstrap validation 
     
Model-2     0.81 (0.72-0.88) 
RVFAC 1 0.91 (0.86-95.0) 0.0001  
O2 pulse 1 0.62 (0.46-0.75) 0.0001  
 
CI: cardiac index; RVFAC: right ventricular fractional area change; O2 pulse: peak oxygen pulse; WHO IV: 
WHO functional class IV. 
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FIGURE LEGENDS 
Figure 1. The event-free survival rates for the overall population included in the study: 
72%, 51% and 30% at 1, 2 and 3 years, respectively, from baseline. 
Figure 2. Correlation between RVFAC and PVR (linear model: r=0.60, p=0.0001, y=47.7-
1.0x). Patients with low peak O2 pulse (< 8.0 ml/beat) and high peak O2 pulse (≥ 8.0 
ml/beat) are reported in the same scatterplot (green circles and blue circles, respectively). 
LEGEND - PVR: pulmonary vascular resistance; RVFAC: right ventricular fractional area 
change. 
Figure 3. RVFAC and the corresponding peak O2 pulse pattern during the 
cardiopulmonary exercise test, in two different IPAH patients. A – preserved RVFAC 
(40.5%) and good exercise performance with adeguate-performing O2 pulse (peak 14.2 
ml/beat); B – preserved RVFAC (40.1%) and poor exercise performance with low O2 pulse 
(peak 7.0 ml/beat). 
LEGEND - IPAH: idiopathic pulmonary arterial hypertension; O2 pulse: peak Oxygen 
pulse; RVFAC: right ventricular fractional area change.  
Figure 4. Comparison of the receiver-operating characteristic (ROC) curves for prediction 
of clinical worsening between Model-1 (black dashed line), including demographic, clinical 
and hemodynamic parameters, and Model-2 (red solid line) adding echocardiographic and 
cardiopulmonary exercise test parameters. A significant improvement in accuracy is 
observed for model-2 in predicting clinical worsening (AUC 0.80 vs 0.66, p=0.0004). 
LEGEND - AUC: area under the curve. 
Figure 5.  Kaplan-Meier event-free survival curves based on the combination of the cut-off 
values of RVFAC and peak O2 pulse. Patients with high RVFAC+high peak O2 pulse 
(group 1) had significantly a better prognosis compared with patients with high 
RVFAC+low peak O2 pulse (group 2; p=0.0001) and low RVFAC+low peak O2 pulse 
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(group 3; p=0.0001). Group 2 patients had a better prognosis compared with group 3 
(p=0.0001), but a worse outcome compared with group 1 (p=0.0001).  
LEGEND - RVFAC: right ventricular fractional area change. 
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Table 1. Hemodynamic, imaging and exercise characteristics of the study population. 
    
Normal values 
Hemodynamics   
mPAP, mmHg 48±15  
RAP, mmHg 7.5±4.1  
CI, l/min/m2 2.4±0.4  
PAWP, mmHg 9±3  
PVR, WU 9.7±5.1  
Echocardiography   
RA Area, cm2 31±10 10-18 
LV-EId 1.4±0.3 1.0 
LV-EIs 1.6±0.6 1.0 
RVEDA, cm2 27.5±7.3 10-25 
RVESA, cm2 17.2±5.9 4-14 
RVFAC, % 37.9±8.6 35-63 
TAPSE, mm 20±4 > 17 
Pericardial effusion 0.3±0.5 0 
Cardiopulmonary exercise test   
HR rest, beats/min 81±14  
HR peak, beats/min 128±24  
VO2 peak, ml/min 1050±359 1390-2780 
VO2/Kg peak, ml/min/Kg 15.3±4.1 20-36 
VO2 pulse peak, ml/beat 8.3±2.7 8-17 
VCO2 peak, ml/min 1050±399 1810-2450 
VE peak, l/min 52.8±20.3 46-110 
PETCO2 peak, mmHg 24.3±5.4 33-41 
VE/VCO2 slope  46±13 26-35 
Work peak, watts 66±30  
Follow-up, days 528±304  
     
 
 
CI: cardiac index; HR: heart rate; LV-EId: left ventricular end-diastolic eccentricity index; LV-EIs: left 
ventricular end-systolic eccentricity index; mPAP: mean pulmonary arterial pressure; PAWP: mean 
pulmonary artery wedge pressure; PETCO2 peak: end-tidal CO2 pressure; PVR: pulmonary vascular 
resistance; RA area: right atrium area; RAP: mean right atrial pressure; RVEDA: right ventricular end-
diastolic area; RVESA: right ventricular end-systolic area; RVFAC: right ventricular fractional area change; 
TAPSE: tricupid anular plane systolic excursion; VCO2 peak: peak carbon dioxide production; VE: minute 
ventilation; VE/VCO2 slope: ventilation to CO2 production slope; VO2 peak: peak oxygen uptake.  
Normal values for echocardiographic parameters are reported from reference 5. 
Normal values for cardiopulmonary exercise test have been calculated from previous reported equations and 
reports considering gender, age, height and weight.46,47  
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Table 2.  Description of different clinical worsening endpoints during follow-up.   
 
  N (%)  
6MW test + WHO class 24/54 (44.4%) 
Hospital admission RHF 16/54 (29.6%) 
Death: 14/54 (25.9/) 
RHF 9/14 (64.2%) 
Sudden death  1/14 (7.1%) 
Non cardiac death 4/14 (28.5%) 
    
 
6MW test: isolated worsening in six-minute walk test > 15% compared to previous test; WHO class: isolated 
worsening in World Health Organization functional class; 6MW test + WHO: worsening in both 6MW test and 
WHO class; Hospital admission RHF: hospital admission for right heart failure; RHF: right heart failure.  
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Table 3. Demographic, clinical, hemodynamic, imaging and exercise differences between 
patients with and without CW. 
  CW  no CW p 
Patients 54 48  
Age, years 52±16 52±12 ns 
BMI 24.8±4 25.9±4 ns 
WHO class 3.0±0.0 2.5±0.5 0.0001 
6MW test, m 397±53 461±59 0.0001 
Hemodynamics    
PAPm, mmHg 55±16 41±11 0.0001 
RAP, mmHg 9.1±4.7 5.9±2.6 0.0001 
CI, l/min/m2 2.3±0.4 2.7±0.3 0.0001 
PAWP, mmHg 8.9±3.5 9.5±3.0 ns 
PVR, WU 12.6±5.3 6.9±2.9 0.0001 
Echocardiography    
RA Area, cm2  34±10 27±9 0.0001 
LV-EId 1.5±0.3                                                                                                      1.2±0.2 0.0001 
LV-EIs 1.8±0.7 1.3±0.2 0.0001 
RVEDA, cm2 31±6 24±6 0.0001 
RVESA, cm2 21±5 14±4 0.0001 
RVFAC, % 32±7 43±6 0.0001 
TAPSE, mm 17.8±3.7 21.1±3.1 0.0001 
Cardiopulmonary exercise test    
HR rest, beats 84±14 79±14 ns 
HR peak, beats 124±26 132±21 ns 
VO2 peak, ml/min 806±165 1276±342 0.0001 
VO2/Kg peak, ml/min/Kg 12.7±2.5 17.8±3.8 0.0001 
VO2 pulse peak, ml/beat 6.5±0.9 10.1±2.6 0.0001 
VE peak, l/min 43.7±10.9 61.0±23,2 0.0001 
VCO2 peak, ml/min 804±214 1287±394 0.0001 
PETCO2 peak, mmHg 22.6±5.2 25.8±5.3 0.003 
VE/VCO2 slope  51±14 43±12 0.001 
Specific therapy    
Ca-channel blockers 4 (7.4%) 5 (10.4%) ns 
ERA 19 (35.1%) 18 (37.5%) ns 
PDE5i 18 (33.3%) 16 (33.3%) ns 
Epoprostenol i.v. 4 (7.4%) 2 (4.1%) ns 
Treprostinil s.c. 9 (16.6%) 7 (14.5%) ns 
        
 
 
6MW test: non-encouraged 6-minute walk test; BMI: body mass index; CI: cardiac index; CW: clinical 
worsening; ERA: endothelin receptor antagonist; HR: heart rate; LV-EId: left ventricular end-diastolic 
eccentricity index; LV-EIs: left ventricular end-systolic eccentricity index; mPAP: mean pulmonary arterial 
pressure; PAWP: mean pulmonary artery wedge pressure PDE5i: phosphodiesterase 5 inhibitor; PETCO2 
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peak: end-tidal CO2 pressure; PVR: pulmonary vascular resistance; RA area: right atrium area; RAP: mean 
right atrial pressure; RVEDA: right ventricular end-diastolic area; RVESA: right ventricular end-systolic area; 
RVFAC: right ventricular fractional area change; TAPSE: tricupid anular plane systolic excursion; VCO2 
peak: peak carbon dioxide production; VE: minute ventilation; VE/VCO2 slope: ventilation to CO2 production 
slope; VO2 peak: peak oxygen uptake; WHO: World Health Organization. 
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Table 4. Univariate analysis of baseline parameters for clinical worsening prediction. 
 
  
Unit Wald HR CI (95%) p  
WHO class 1 9.9 24.2 3.3-175 <0.0001 
6MW test, m 1 16.6 0.99 0.98-0.99 <0.0001 
Hemodynamics      
RAP, mmHg 1 13.3 1.10 1.04-1.16 <0.0001  
CI, l/min/m2 1 27.7 0.14 0.07-0.29 <0.0001   
PVR, WU 1 35.4 1.16 1.10-1.22 <0.0001  
Echocardiography      
RA Area, cm2 1 11.4 1.04  1.01-1.06 0.001 
LV-EId 1 20.7 5.37 2.60-11.06 <0.0001 
LV-EIs 1 32.9 3.42 2.25-5.22 <0.0001 
RVEDA, cm2 1 21.6 1.08 1.04-1.11 <0.0001 
RVESA, cm2 1 39.1 1.15 1.10-1.20 <0.0001 
RVFAC, % 1 51.1 0.86 0.83-0.90 <0.0001 
TAPSE, mm 1 18.0 0.85 0.79-0.92 <0.0001 
Pericardial effusion 1 7.3 2.16 1.23-3.77 0.007 
Cardiopulmonary 
exercise test 
     
HR peak, beats/min 1 4.7 0.98 0.97-0.99 0.02 
VO2/Kg peak, ml/min/Kg 1 28.1 0.77 0.70-0.85 <0.0001 
VO2 pulse peak, ml/beat 1 35.5 0.48 0.38-0.61 <0.0001 
VE peak, l/min 1 15.2 0.95 0.92-0.97 <0.0001 
VE/VCO2 slope  1 7.1 1.02 1.00-1.04 0.007 
Work peak, watts 1 11.7 0.97 0.96-0.98 0.001 
        
 
6MW test: non-encouraged 6-minute walk test; BMI: body mass index; CI: cardiac index; HR: heart rate; LV-
EId: left ventricular end-diastolic eccentricity index; LV-EIs: left ventricular end-systolic eccentricity index; 
mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; RA area: right atrium area; 
RAP: mean right atrial pressure; RVEDA: right ventricular end-diastolic area; RVESA: right ventricular end-
systolic area; RVFAC: right ventricular fractional area change; TAPSE: tricupid anular plane systolic excursion; 
VCO2 peak: peak carbon dioxide production; VE: minute ventilation; VE/VCO2 slope: ventilation to CO2 
production slope; VO2 peak: peak oxygen uptake; Wald: ratio of the square of the regression coefficient to the 
square of the standard error of the coefficient; WHO: World Health Organization. 
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Table 5. Cox regression models for clinical worsening prediction (Model-1 and Model-2) 
and bootstrap estimates of Cox proportional hazard analysis. 
 
 Unit HR (95% CI) p C-statistic (95% CI) 
Model-1     0.66 (0.55-0.76) 
WHO class 1 15.8 (2.15-116) 0.007  
CI 0.5 0.49 (0.33-0.70) 0.0001  
Model-2     0.81 (0.72-0.88) 
RVFAC 1 0.91 (0.86-95.0) 0.0001  
O2 pulse 1 0.62 (0.48-0.79) 0.0001  
Bootstrap validation 
     
Model-2     0.81 (0.72-0.88) 
RVFAC 1 0.91 (0.86-95.0) 0.0001  
O2 pulse 1 0.62 (0.46-0.75) 0.0001  
 
CI: cardiac index; RVFAC: right ventricular fractional area change; O2 pulse: peak oxygen pulse; WHO IV: 
WHO functional class IV. 
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